Enrique Grande Pulido

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N. et al. · The Lancet · 2017 · 177 citations · Full text

Medicine, Oncology, Pharmacology +15

Potential Role of Sugar Transporters in Cancer and Their Relationship with Anticancer Therapy

Angélica Figueroa, Enrique Grande Pulido, Rosario García Campelo et al. · International Journal of Endocrinology · 2010 · 175 citations · Full text

Medicine, Oncology, Pharmacology +17

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

Robert J. Motzer, Camillo Porta, Masatoshi Eto et al. · Journal of Clinical Oncology · 2024 · 158 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study

Yohann Loriot, Jonathan E. Rosenberg, Tom Powles et al. · Annals of Oncology · 2016 · 24 citations

Medicine, Oncology, Pharmacotherapy +14

PAZONET: Results of a phase II trial of pazopanib as a sequencing treatment in progressive metastatic neuroendocrine tumors (NETs) patients (pts), on behalf of the Spanish task force for NETs (GETNE)—NCT01280201.

Enrique Grande Pulido, Daniel Castellano, Rocio García‐Carbonero et al. · Journal of Clinical Oncology · 2012 · 17 citations

Medicine, Oncology, Pharmacology +17